Series A · Biotech · Marseille, France · Founded 2024 · 11–50 employees
Adcytherix is a clinical-stage biopharmaceutical company that develops novel and proprietary antibody-drug conjugates to target advanced solid tumors. The company leverages its proprietary ADCX-Engine platform to engineer therapies designed to overcome payload resistance and expand the therapeutic window. Adcytherix has progressed its lead therapeutic candidate, ADCX-020, into Phase 1 clinical trials. The company secured a major milestone by raising a EUR 105 million Series A funding round in October 2025 to advance its development pipeline. Adcytherix was founded by the experienced entrepreneurial team behind Emergence Therapeutics, which was previously acquired by Eli Lilly.
No open roles listed right now.